TAVR is a safe, effective treatment for patients with bicuspid valves, according to research published in JACC: Cardiovascular Interventions.

Reported in 2018 by anesthesiologists at the University of Florida College of Medicine in Gainesville, the case suggested a message to TAVR operators: “Vigilance and a high degree of suspicion” are critical for avoiding the potentially severe hemodynamic consequences of HCM associated with aortic stenosis, the authors asserted (J Med Case Rep 2018;18;12[1]:372).

An analysis of PARTNER 2 data published in the New England Journal of Medicine Jan. 29 suggests five-year post-op outcomes are similar among heart patients who undergo either transcatheter or surgical aortic valve replacement.

The latest numbers on cardiovascular deaths put the focus on innovative ways to point the trend line down again.

Patients with severe aortic stenosis who undergo TAVR enjoy a minor but significant sustained health benefit that isn’t mirrored in patients who opt for surgical AVR, according to research reported at TCT 2019 in San Francisco.

The transcarotid approach to TAVR is becoming more common, according to research presented at TVT.19.

The Society of Cardiovascular Computed Tomography (SCCT) has issued an updated guidance for the use of CT in transcatheter aortic valve implantation (TAVI) and transcatheter aortic valve replacement (TAVR) procedures. The full document can be read in the Journal of Cardiovascular Computed Tomography.

One morning last year, a patient checked into a hospital in Canada as the first TAVR case of the day, and they were discharge by that evening. It was an eyebrow-raising feat for a procedure that typically requires several days of hospitalization.